272 related articles for article (PubMed ID: 26824188)
21. Phosphosignature predicts dasatinib response in non-small cell lung cancer.
Klammer M; Kaminski M; Zedler A; Oppermann F; Blencke S; Marx S; Müller S; Tebbe A; Godl K; Schaab C
Mol Cell Proteomics; 2012 Sep; 11(9):651-68. PubMed ID: 22617229
[TBL] [Abstract][Full Text] [Related]
22. Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines.
Geeleher P; Cox NJ; Huang RS
Genome Biol; 2014 Mar; 15(3):R47. PubMed ID: 24580837
[TBL] [Abstract][Full Text] [Related]
23. A transcription/translation-based gene signature predicts resistance to chemotherapy in breast cancer.
He DX; Xia YD; Gu XT; Jin J; Ma X
J Pharm Biomed Anal; 2015 Jan; 102():500-8. PubMed ID: 25459950
[TBL] [Abstract][Full Text] [Related]
24. A gene expression signature predicts survival of patients with stage I non-small cell lung cancer.
Lu Y; Lemon W; Liu PY; Yi Y; Morrison C; Yang P; Sun Z; Szoke J; Gerald WL; Watson M; Govindan R; You M
PLoS Med; 2006 Dec; 3(12):e467. PubMed ID: 17194181
[TBL] [Abstract][Full Text] [Related]
25. Implications of MicroRNAs in the Treatment of Gefitinib-Resistant Non-Small Cell Lung Cancer.
Sin TK; Wang F; Meng F; Wong SC; Cho WC; Siu PM; Chan LW; Yung BY
Int J Mol Sci; 2016 Feb; 17(2):237. PubMed ID: 26891293
[TBL] [Abstract][Full Text] [Related]
26. ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer.
Govindan R; Mandrekar SJ; Gerber DE; Oxnard GR; Dahlberg SE; Chaft J; Malik S; Mooney M; Abrams JS; Jänne PA; Gandara DR; Ramalingam SS; Vokes EE
Clin Cancer Res; 2015 Dec; 21(24):5439-44. PubMed ID: 26672084
[TBL] [Abstract][Full Text] [Related]
27. Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation.
Zou M; Xia S; Zhuang L; Han N; Chu Q; Chao T; Peng P; Chen Y; Gui Q; Yu S
Int J Oncol; 2013 Jun; 42(6):2094-102. PubMed ID: 23588221
[TBL] [Abstract][Full Text] [Related]
28. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients.
Yauch RL; Januario T; Eberhard DA; Cavet G; Zhu W; Fu L; Pham TQ; Soriano R; Stinson J; Seshagiri S; Modrusan Z; Lin CY; O'Neill V; Amler LC
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8686-98. PubMed ID: 16361555
[TBL] [Abstract][Full Text] [Related]
29. Comparative profiling of the novel epothilone, sagopilone, in xenografts derived from primary non-small cell lung cancer.
Hammer S; Sommer A; Fichtner I; Becker M; Rolff J; Merk J; Klar U; Hoffmann J
Clin Cancer Res; 2010 Mar; 16(5):1452-65. PubMed ID: 20179216
[TBL] [Abstract][Full Text] [Related]
30. Implication of epithelial-mesenchymal transition in IGF1R-induced resistance to EGFR-TKIs in advanced non-small cell lung cancer.
Zhou J; Wang J; Zeng Y; Zhang X; Hu Q; Zheng J; Chen B; Xie B; Zhang WM
Oncotarget; 2015 Dec; 6(42):44332-45. PubMed ID: 26554308
[TBL] [Abstract][Full Text] [Related]
31. Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples.
Ishii H; Azuma K; Sakai K; Kawahara A; Yamada K; Tokito T; Okamoto I; Nishio K; Hoshino T
Oncotarget; 2015 Oct; 6(31):30850-8. PubMed ID: 26334838
[TBL] [Abstract][Full Text] [Related]
32. Lung Cancer Genomics in the Era of Accelerated Targeted Drug Development.
Wijesinghe P; Bollig-Fischer A
Adv Exp Med Biol; 2016; 890():1-23. PubMed ID: 26703796
[TBL] [Abstract][Full Text] [Related]
33. cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance.
Villeneuve DJ; Hembruff SL; Veitch Z; Cecchetto M; Dew WA; Parissenti AM
Breast Cancer Res Treat; 2006 Mar; 96(1):17-39. PubMed ID: 16322897
[TBL] [Abstract][Full Text] [Related]
34. Genes suppressed by DNA methylation in non-small cell lung cancer reveal the epigenetics of epithelial-mesenchymal transition.
Lin SH; Wang J; Saintigny P; Wu CC; Giri U; Zhang J; Menju T; Diao L; Byers L; Weinstein JN; Coombes KR; Girard L; Komaki R; Wistuba II; Date H; Minna JD; Heymach JV
BMC Genomics; 2014 Dec; 15(1):1079. PubMed ID: 25486910
[TBL] [Abstract][Full Text] [Related]
35. [DDP-sensitivity-related genes in 10 lung cancer cell lines].
Li CH; Cai L; Chen XS; Meng QW; Sui GJ
Zhonghua Zhong Liu Za Zhi; 2008 Jun; 30(6):418-21. PubMed ID: 19024514
[TBL] [Abstract][Full Text] [Related]
36. Role of 14-3-3σ in resistance to cisplatin in non-small cell lung cancer cells.
Cetintas VB; Tetik A; Cok G; Kucukaslan AS; Kosova B; Gunduz C; Veral A; Eroglu Z
Cell Biol Int; 2013 Jan; 37(1):78-86. PubMed ID: 23339090
[TBL] [Abstract][Full Text] [Related]
37. Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models.
Spoerke JM; O'Brien C; Huw L; Koeppen H; Fridlyand J; Brachmann RK; Haverty PM; Pandita A; Mohan S; Sampath D; Friedman LS; Ross L; Hampton GM; Amler LC; Shames DS; Lackner MR
Clin Cancer Res; 2012 Dec; 18(24):6771-83. PubMed ID: 23136191
[TBL] [Abstract][Full Text] [Related]
38. Pareto Optimization Identifies Diverse Set of Phosphorylation Signatures Predicting Response to Treatment with Dasatinib.
Klammer M; Dybowski JN; Hoffmann D; Schaab C
PLoS One; 2015; 10(6):e0128542. PubMed ID: 26083411
[TBL] [Abstract][Full Text] [Related]
39. Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.
Howe GA; Xiao B; Zhao H; Al-Zahrani KN; Hasim MS; Villeneuve J; Sekhon HS; Goss GD; Sabourin LA; Dimitroulakos J; Addison CL
PLoS One; 2016; 11(3):e0150567. PubMed ID: 26962872
[TBL] [Abstract][Full Text] [Related]
40. Gene Expression Signatures Predictive of Bevacizumab/Erlotinib Therapeutic Benefit in Advanced Nonsquamous Non-Small Cell Lung Cancer Patients (SAKK 19/05 trial).
Franzini A; Baty F; Macovei II; Dürr O; Droege C; Betticher D; Grigoriu BD; Klingbiel D; Zappa F; Brutsche MH
Clin Cancer Res; 2015 Dec; 21(23):5253-63. PubMed ID: 25922429
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
